KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Taxes (2016 - 2020)

Supernus Pharmaceuticals (SUPN) has disclosed Change in Taxes for 5 consecutive years, with -$25.1 million as the latest value for Q3 2020.

  • On a quarterly basis, Change in Taxes fell 1268.42% to -$25.1 million in Q3 2020 year-over-year; TTM through Sep 2020 was -$4.9 million, a 31.72% decrease, with the full-year FY2019 number at -$9.9 million, down 178.97% from a year prior.
  • Change in Taxes was -$25.1 million for Q3 2020 at Supernus Pharmaceuticals, down from $15.9 million in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $15.9 million in Q2 2020 to a low of -$25.1 million in Q3 2020.
  • A 5-year average of -$5000.0 and a median of $782000.0 in 2016 define the central range for Change in Taxes.
  • Peak YoY movement for Change in Taxes: skyrocketed 7481.82% in 2017, then tumbled 24176.12% in 2018.
  • Supernus Pharmaceuticals' Change in Taxes stood at -$804000.0 in 2016, then soared by 1275.25% to $9.4 million in 2017, then tumbled by 59.48% to $3.8 million in 2018, then crashed by 162.03% to -$2.4 million in 2019, then tumbled by 954.78% to -$25.1 million in 2020.
  • Per Business Quant, the three most recent readings for SUPN's Change in Taxes are -$25.1 million (Q3 2020), $15.9 million (Q2 2020), and $6.7 million (Q1 2020).